Prudential Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Prudential Financial’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Sell	10,995 -680	-6%	-$9.44K	﹤0.01%	2264
2026 Q1	$171K	Buy	+11,675	New	+$186K	﹤0.01%	2166
2019 Q2	–	Sell	-14,939	Closed	-$60K	–	2460
2019 Q1	$60K	Sell	14,939 -6,606	-31%	-$27.9K	﹤0.01%	2397
2018 Q4	$79K	Buy	21,545 +2,805	+15%	+$19.1K	﹤0.01%	2318
2018 Q3	$161K	Sell	18,740 -200	-1%	-$2K	﹤0.01%	2356
2018 Q2	$208K	Buy	+18,940	New	+$211K	﹤0.01%	2335

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Prudential Financial's CRVS Position: Q2 2026 in Review

Prudential Financial reduced its Corvus Pharmaceuticals (CRVS) stake by 5.8% in Q2 2026, selling an estimated $9.44K and leaving 10,995 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2264.

Prudential Financial first reported a position in CRVS in Q2 2018 and has held it in 6 quarters since. The position peaked at $208K in Q2 2018. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Prudential Financial held 10,995 shares of Corvus Pharmaceuticals worth $164K as of Q2 2026.
Prudential Financial sold 680 Corvus Pharmaceuticals shares in Q2 2026, an estimated $9.44K.
Corvus Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2264 holding.
Prudential Financial first reported a position in Corvus Pharmaceuticals in Q2 2018 and has held it in 6 quarters since.
Prudential Financial's Corvus Pharmaceuticals position peaked at $208K in Q2 2018.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.